UBTFL9

Across TCGA pan-cancer cohorts, UBTFL9 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of UBTFL9’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where UBTFL9 RNA is repressed in tumor relative to normal tissue. In most cancer types UBTFL9 is over-expressed in tumor, although a few such as KIRP and KICH show the opposite, repressed pattern.

KIRP, KICH, and BRCA are the cancer types where UBTFL9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in UBTFL9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	All	−0.038	<.001	8	view →
KICH	All	All	−0.047	.002	5	view →
BRCA	Female	All	−0.058	<.001	4	view →
PRAD	All	All	+0.224	<.001	2	view →
HNSC	All	III,IV	+0.032	.021	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

UBTFL9–KIRP

Open the KIRP breakdown →